Receipt of Research & Development Tax Incentive
Filed with ASX · · 1 page · English
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- 2nd Generation, ColoSTAT Multiplex Alpha Kit Outperforms
- Board Renewal / Composition Update
- Platform Expansion - Gastric Cancer Diagnostic Test Update
- Product and Market Update - Phase 2 Milestone
- Jun 24 Quarterly Activities Report and Appendix 4C
Later from Rhythm Biosciences
- Strong Demand in Share Placement to Raise $3.5 million
- Market Update - All End of CY24 Milestones Attained
- Pause in Trading
- RHY Acquires Genetype Genetic Risk Assessment Business
- Completion of Genetype Risk Assessment Portfolio Acquisition
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences